These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11192745)

  • 61. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT II, RESTORE, and EPILOG trials into perspective.
    Tcheng JE
    Am J Cardiol; 1996 Aug; 78(3A):35-40. PubMed ID: 8751845
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: results from TARGET (do Tirofiban and ReoPro give similar efficacy trial?).
    Kalyanasundaram A; Blankenship JC; Berger P; Herrmann H; McClure R; Moliterno D
    Catheter Cardiovasc Interv; 2007 Apr; 69(5):623-9. PubMed ID: 17192960
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes.
    Braunwald E; Maseri A; Armstrong PW; Califf RM; Gibler WB; Hamm CW; Simoons ML; Van de Werf F
    Eur Heart J; 1998 Apr; 19 Suppl D():D22-30. PubMed ID: 9597519
    [TBL] [Abstract][Full Text] [Related]  

  • 65. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II.
    Koster A; Meyer O; Fischer T; Kukucka M; Krabatsch T; Bauer M; Kuppe H; Hetzer R
    J Thorac Cardiovasc Surg; 2001 Dec; 122(6):1254-5. PubMed ID: 11726910
    [No Abstract]   [Full Text] [Related]  

  • 66. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Antithrombotic treatment of acute coronary syndromes without ST-segment elevation].
    Radke PW; Schunkert H
    Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S204-7. PubMed ID: 17109249
    [No Abstract]   [Full Text] [Related]  

  • 68. Tirofiban for catheter intervention in acute myocardial infarction?
    Büttner HJ; Neumann FJ
    Eur Heart J; 2004 May; 25(10):807-9. PubMed ID: 15140527
    [No Abstract]   [Full Text] [Related]  

  • 69. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
    Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
    JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization].
    Albuquerque A
    Rev Port Cardiol; 2001 Sep; 20(9):927-8. PubMed ID: 11763604
    [No Abstract]   [Full Text] [Related]  

  • 71. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
    Popma JJ; Satler LF
    J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
    Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R;
    JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Pathogenesis and therapy of the acute coronary syndrome: differentiated advantage of glycoprotein IIb/IIIa receptor antagonists for high-risk patients].
    Münzel TF; Post F
    Dtsch Med Wochenschr; 2006 Nov; 131(47 Suppl 7):S215-8. PubMed ID: 17109252
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Adjunctive therapies in the cath lab. Combination of tirofiban and alteplase in acute myocardial infarction.
    Arjomand H; Sokil AB; Arjmand R; Fischer HA; Wolf NM
    J Invasive Cardiol; 2001 Sep; 13(9):647-50. PubMed ID: 11533504
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Platelet membrane glycoproteins as site of pharmacological intervention in the treatment of coronary disease].
    Neumann FJ; Gawaz M; Schömig A
    Dtsch Med Wochenschr; 1997 Oct; 122(40):1224-30. PubMed ID: 9378047
    [No Abstract]   [Full Text] [Related]  

  • 76. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial.
    Stone GW; Ware JH; Bertrand ME; Lincoff AM; Moses JW; Ohman EM; White HD; Feit F; Colombo A; McLaurin BT; Cox DA; Manoukian SV; Fahy M; Clayton TC; Mehran R; Pocock SJ;
    JAMA; 2007 Dec; 298(21):2497-506. PubMed ID: 18056903
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Impact of GP IIb/IIIa antagonists in interventional cardiology].
    Scheller B; Hennen B; Böhm M; Nickenig G
    Dtsch Med Wochenschr; 2003 Feb; 128(6):281-7. PubMed ID: 12571800
    [No Abstract]   [Full Text] [Related]  

  • 78. Upstream use of tirofiban in patients admitted for an acute coronary syndrome in hospitals with or without facilities for invasive management. PRISM-PLUS Investigators.
    Théroux P; Alexander J; Dupuis J; Pesant Y; Gervais P; Grandmont D; Kouz S; Laramée P; Huynh T; Barr E; Sax FL;
    Am J Cardiol; 2001 Feb; 87(4):375-80. PubMed ID: 11179517
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antithrombotic therapy in patients with acute coronary syndromes.
    Levine GN; Ali MN; Schafer AI
    Arch Intern Med; 2001 Apr; 161(7):937-48. PubMed ID: 11295956
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antithrombotic agents: implications in dentistry.
    Little JW; Miller CS; Henry RG; McIntosh BA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 May; 93(5):544-51. PubMed ID: 12075203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.